Amplia Therapeutics (ASX:ATX) Common Stock: A$193.43 Mil (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Common Stock?

Amplia Therapeutics ASX:ATX 36 Common Stock is A$193.43 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's quarterly common stock increased from Mar. 2025 (A$167.39 Mil) to Sep. 2025 (A$193.43 Mil) but then stayed the same from Sep. 2025 (A$193.43 Mil) to Mar. 2026 (A$193.43 Mil).

Amplia Therapeutics's annual common stock increased from Mar. 2024 (A$151.53 Mil) to Mar. 2025 (A$167.39 Mil) and increased from Mar. 2025 (A$167.39 Mil) to Mar. 2026 (A$193.43 Mil).

Amplia Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Common Stock Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 151.51 151.53 151.53 167.39 193.43

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.53 155.63 167.39 193.43 193.43
ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$193.43 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Common Stock of A$193.43 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Common Stock too high?
Amplia Therapeutics' current Common Stock is A$193.43 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Common Stock compare to VRTX and REGN?
Amplia Therapeutics' Common Stock of A$193.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Common Stock is A$193.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Common Stock of A$193.43 Mil. The current Common Stock is A$193.43 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Common Stock is A$193.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price